An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo. More than a year later, Pfizer has yet to embark on large-scale human trials of a COVID-19 oral treatment - something it says it hopes to start by July. Pfizer’s experience underscores the challenges drugmakers face in developing an oral treatment for the virus. Pfizer Chief Executive Albert Bourla has said the company could seek emergency authorization in the United States for a COVID-19 pill as soon as late this year. In March of this year, Pfizer began early-stage human trials in the United States of its experimental oral COVID-19 treatment, known as PF-07321332.

Source: Standard Digital May 21, 2021 12:25 UTC